Search

Syndax Pharmaceuticals Inc

Deschisă

SectorSănătate

20.05 0.6

Rezumat

Modificarea prețului

24h

Curent

Minim

19.62

Maxim

20.14

Indicatori cheie

By Trading Economics

Venit

-6.7M

-49M

Vânzări

7.9M

73M

EPS

-0.55

Marjă de profit

-67.817

Angajați

298

EBITDA

-5.9M

-37M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+85.81% upside

Dividende

By Acuity

Următoarele câștiguri

2 nov. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

43M

1.7B

Deschiderea anterioară

19.45

Închiderea anterioară

20.05

Sentimentul știrilor

By Acuity

54%

46%

283 / 340 Clasament în Healthcare

Syndax Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

25 aug. 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24 aug. 2026, 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21 aug. 2026, 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20 aug. 2026, 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19 aug. 2026, 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18 aug. 2026, 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17 aug. 2026, 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14 aug. 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12 aug. 2026, 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11 aug. 2026, 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

10 aug. 2026, 19:36 UTC

Syndax Pharmaceuticals shares are lower amid broader market volatility and rising oil prices due to geopolitical tensions in the Strait of Hormuz.

6 aug. 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

5 aug. 2026, 20:02 UTC

News
Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

4 aug. 2026, 23:11 UTC

News

Syndax Pharmaceuticals shares are lower in after-market hours following a second-quarter earnings miss, reporting a net loss of $49.4 million and revenue of $72.8 million.

3 aug. 2026, 19:16 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares are higher amid a broader market rally. The stock remains below its 20-day moving average and near the lower end of its one-month range.

31 iul. 2026, 20:06 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares declined after first-quarter results showed lower performance. Broader market pressures from rising yields and oil prices contributed to the decline.

30 iul. 2026, 17:06 UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

29 iul. 2026, 19:56 UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

28 iul. 2026, 20:51 UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

27 iul. 2026, 20:06 UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

24 iul. 2026, 19:52 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

22 iul. 2026, 19:06 UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Comparație

Modificare preț

Syndax Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

85.81% sus

Prognoză pe 12 luni

Medie 37.33 USD  85.81%

Maxim 57 USD

Minim 26 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSyndax Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

10 ratings

10

Cumpărare

0

Păstrare

0

Vânzare

Sentiment

By Acuity

283 / 340 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
help-icon Live chat